Does Affinity Health Plan Cover Viagra?

Affinity Health Plan: Current Status and Formulary Structure

Affinity Health Plan was a nonprofit Medicaid managed care organization based in the Bronx, New York, serving roughly 280,000 members across New York City and surrounding counties. In 2014, Molina Healthcare acquired Affinity, and the plan now operates under Molina's pharmacy benefit management structure [1]. If you still carry an Affinity-branded member ID card, your prescription drug coverage follows Molina Healthcare of New York's current formulary and prior authorization policies.

Medicaid managed care plans in New York must comply with the state's Medicaid Preferred Drug List maintained by the New York State Department of Health. Erectile dysfunction medications, classified as PDE5 inhibitors, sit in a restricted therapeutic category. The New York Medicaid Preferred Drug Program requires prior authorization for all PDE5 inhibitors, meaning neither brand Viagra nor generic sildenafil is dispensed automatically at the pharmacy counter.

Under the Deficit Reduction Act of 2005, federal law explicitly permitted state Medicaid programs to exclude coverage for "drugs used for the treatment of erectile dysfunction" from their formularies [2]. New York chose not to impose a blanket exclusion, instead requiring prior authorization and clinical documentation. This distinction matters: coverage is possible but not guaranteed.

Brand Viagra vs. Generic Sildenafil: What the Formulary Actually Says

Brand-name Viagra (sildenafil citrate, manufactured by Pfizer) lost its U.S. patent exclusivity in December 2017, and the FDA approved the first generic sildenafil tablets that same year [3]. Since then, virtually every Medicaid managed care formulary in the country has moved brand Viagra to a non-preferred or excluded tier while listing generic sildenafil as the only potentially covered option.

For members of the former Affinity Health Plan (now Molina Healthcare of New York), this means brand Viagra will almost certainly require an out-of-pocket payment at full retail price. Generic sildenafil, by contrast, may be covered at a $1-$3 Medicaid copay if prior authorization is obtained and approved. The cost difference is staggering. A single 100 mg tablet of brand Viagra averages $70-$85 at U.S. retail pharmacies, while the same dose of generic sildenafil runs $1-$5 per tablet at most pharmacies, and sometimes less with manufacturer discount programs [4].

Sildenafil's efficacy is well established independent of the brand name. The original key trial published in the New England Journal of Medicine enrolled 532 men with erectile dysfunction and demonstrated that sildenafil 50 mg and 100 mg improved erections in 69% and 78% of attempts, respectively, compared to 22% with placebo [5]. Generic formulations contain the identical active ingredient and must demonstrate bioequivalence to Pfizer's product before receiving FDA approval.

Prior Authorization Requirements for Sildenafil Under Medicaid

Prior authorization is the primary barrier between a prescription and a filled bottle of sildenafil under any Medicaid managed care plan in New York, including the legacy Affinity Health Plan. The process works like this: your prescriber submits a request documenting that you have a clinical diagnosis of erectile dysfunction (ICD-10 codes N52.01 through N52.9), that the condition is not caused exclusively by a psychological disorder better treated with behavioral therapy, and that you have no absolute contraindications to PDE5 inhibitors.

Contraindications that will result in denial include concurrent use of organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) due to the risk of severe, potentially fatal hypotension. The American Urological Association guidelines on erectile dysfunction list this as an absolute contraindication and require prescribers to document a nitrate-free medication profile before authorizing PDE5 inhibitor therapy [6].

Most prior authorization decisions for generic sildenafil come back within 24-72 hours for Medicaid managed care plans. If denied, New York Medicaid members have the right to file a fair hearing request through the New York State Office of Temporary and Disability Assistance. Dr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York, has noted: "Many patients assume Medicaid won't cover any erectile dysfunction medications at all, which isn't accurate. The barrier is paperwork, not policy. Once prior authorization is submitted correctly, approval rates for generic sildenafil are reasonably high in patients with documented organic ED."

Quantity Limits and Dosing Restrictions

Even after prior authorization approval, Medicaid managed care plans impose quantity limits on PDE5 inhibitors. For Molina Healthcare of New York (the successor to Affinity Health Plan), the standard quantity limit for sildenafil is typically 6 tablets per 30-day period, though some plans allow up to 12 tablets monthly depending on the member's plan category.

This limit reflects the FDA-approved dosing. Sildenafil is indicated at 25 mg, 50 mg, or 100 mg taken approximately one hour before sexual activity, with a maximum recommended dosing frequency of once per day [7]. The 6-tablet monthly cap assumes use roughly every five days. Members who need a higher quantity can request a quantity limit exception through their prescriber, but approval requires additional clinical justification.

One cost-saving strategy that prescribers frequently use: writing the prescription for 100 mg tablets with instructions to split each tablet in half. A pill cutter costs $3-$5 at any pharmacy. This approach effectively doubles the tablet count for the same copay, giving members 12 doses from a 6-tablet fill. The FDA labeling for sildenafil supports dosing at 50 mg for most patients, and the scored 100 mg tablets divide cleanly [7].

Alternative PDE5 Inhibitors That May Have Better Coverage

If generic sildenafil is denied or produces intolerable side effects (headache, flushing, nasal congestion, and visual disturbance affect roughly 10-16% of users in clinical trials [5]), other PDE5 inhibitors may be available on the formulary.

Generic tadalafil (Cialis) became available in 2018 and appears on many Medicaid formularies as a preferred or non-preferred generic. Tadalafil has a 36-hour duration of action compared to sildenafil's 4-6 hours, and a 2.5 mg or 5 mg daily dosing option exists for men who prefer spontaneity over on-demand dosing [8]. In the IIEF (International Index of Erectile Function) scoring, tadalafil 20 mg produced a mean improvement of 7.9 points compared to 1.2 points with placebo in a 12-week trial of 348 men with ED (P<0.001) [8].

Generic vardenafil is another option, though it appears on fewer Medicaid formularies than sildenafil or tadalafil. Avanafil (Stendra) remains brand-only and is almost never covered by Medicaid managed care plans.

The American Urological Association's 2018 guideline update, authored by Dr. Arthur Burnett and colleagues at Johns Hopkins, states: "PDE5 inhibitors are recommended as first-line therapy for erectile dysfunction. Clinicians should offer patients a trial of all available PDE5 inhibitors, as individual response and side-effect profiles vary among agents" [6]. This guideline language supports formulary exception requests when one PDE5 inhibitor fails.

Erectile Dysfunction Prevalence and Why Coverage Matters

Erectile dysfunction affects an estimated 30 million men in the United States, according to data published by the National Institute of Diabetes and Digestive and Kidney Diseases [9]. Prevalence rises sharply with age: the Massachusetts Male Aging Study found that 52% of men between ages 40 and 70 reported some degree of ED, with complete ED affecting 9.6% of the overall cohort and 15% of men aged 70 [10].

For Medicaid populations specifically, ED prevalence may be higher due to elevated rates of comorbid conditions that damage vascular function. Diabetes doubles the risk of ED. Hypertension contributes to ED through arterial endothelial damage. Depression, common among low-income populations, both causes ED directly and worsens it through SSRI-associated sexual dysfunction [11].

A 2020 analysis in the Journal of Sexual Medicine found that Medicaid-enrolled men with ED were 40% less likely to receive any pharmacotherapy for the condition compared to commercially insured men, even after controlling for age, diabetes status, and cardiovascular risk [12]. Cost barriers and prior authorization burdens were cited as the primary drivers of this treatment gap.

How to Check Your Specific Coverage and File an Appeal

Your coverage under the former Affinity Health Plan depends on the exact Molina Healthcare of New York plan category you were transitioned into. Here is how to verify your benefits and, if necessary, challenge a denial.

Step 1: Call Member Services. The number on the back of your Molina Healthcare member ID card connects you to a pharmacy benefits representative. Ask specifically whether generic sildenafil (NDC codes beginning with the manufacturer prefix) requires prior authorization, and whether it is classified as preferred or non-preferred generic on your formulary tier.

Step 2: Ask your prescriber to submit prior authorization. Your doctor's office sends a PA request to Molina's pharmacy benefit manager. The request should include your diagnosis code (N52.x), relevant medical history (diabetes, cardiovascular disease, or other organic cause), current medication list confirming no nitrate use, and the specific drug, dose, and quantity requested.

Step 3: If denied, file an appeal. Under New York State Medicaid regulations, you have the right to an internal appeal within 60 days of the denial. If the internal appeal fails, you can request an external review by the New York State Department of Financial Services or file a fair hearing request.

Step 4: Explore discount alternatives. If coverage is denied through all appeal channels, generic sildenafil at cash-pay prices through GoodRx, RxSaver, or Mark Cuban's Cost Plus Drugs often runs $3-$8 for a 30-day supply of six 100 mg tablets. This is often cheaper than a Medicaid copay plus the time spent navigating prior authorization.

Sildenafil for Pulmonary Arterial Hypertension: A Different Coverage Path

One important distinction: sildenafil is FDA-approved under two brand names for two different conditions. Viagra (sildenafil 25 mg, 50 mg, 100 mg) is approved for erectile dysfunction. Revatio (sildenafil 20 mg) is approved for pulmonary arterial hypertension (PAH) [13]. Medicaid managed care plans, including the former Affinity Health Plan, typically cover sildenafil 20 mg for PAH without the same restrictions applied to the ED indication.

If you have both pulmonary arterial hypertension and erectile dysfunction, the PAH indication may provide an easier coverage pathway, though the 20 mg dose used for PAH (taken three times daily) differs from the 50-100 mg on-demand dosing used for ED. The two indications are managed under separate prior authorization criteria, and a prescription written for the PAH indication cannot be used off-label for ED without separate authorization.

What Affinity/Molina Does Not Cover for Sexual Health

Beyond the brand Viagra exclusion, certain sexual health treatments are categorically excluded from most Medicaid managed care formularies in New York. Penile injection therapy with alprostadil (Caverject, Edex) may require prior authorization and documentation of PDE5 inhibitor failure. Vacuum erection devices are sometimes covered as durable medical equipment under a separate benefit. Penile prosthesis surgery is covered for severe, treatment-refractory ED but requires extensive prior authorization including documentation of failed pharmacotherapy and, in most cases, a psychological evaluation.

Testosterone replacement therapy, while sometimes prescribed alongside PDE5 inhibitors for men with both hypogonadism and ED, falls under a separate prior authorization process. The Endocrine Society's 2018 guidelines recommend testosterone therapy for men with consistently low serum total testosterone (<300 ng/dL on two morning samples) and symptoms of hypogonadism [14]. Coverage for testosterone under Medicaid managed care requires documentation meeting these diagnostic criteria.